Pharmaceutical New Product Planning: Structure and Activities to Drive Growth & Profitability

Research Info
Download FREE Excerpt
ID: 5008
Price: $9000
Pages/Slides: 176
Features:
 40 Info Graphics
 60 Data Graphics
 700 Metrics
 50 Narratives
Delivery Format:
 Online PDF Document
Non-members: Click here for a complimentary excerpt of Pharmaceutical New Product Planning: Structure and Activities to Drive Growth & Profitability



Study Overview
Pharmaceutical and biotech companies are increasingly under pressure to deliver effective new products in shorter time frames while minimizing development costs. The structure, activities, and resources of New Product Planning (NPP) groups are critical to focusing new product development and optimizing product portfolios.

This research identifies the structure and roles of NPP groups as well as the full set of activities that NPP groups perform across the development cycle. The study details the strengths and weaknesses of various NPP organizational structures and how the operational characteristics of the NPP function evolves as a company matures. In addition, the research examines dozens of NPP development activities in terms of timing during the development process, intended outcomes and value for the organization.


Executives, directors, and managers in New Product Planning roles at pharmaceutical companies can use this report to implement structural changes to NPP operations and to enhance the interaction between Global and Regional NPP groups. In addition, this research provides leaders wtih actionable insights for strengthening the product development process of their organization to gain an overall competitive advantage in the marketplace.

NOTE: The data in this research are segmented into three parts: Global NPP Function for Large Pharma, Global NPP Function for Small Pharma and Regional NPP Function for Large Pharma.

Key Topics

  • NPP Group Structures, Roles and Responsibilities
  • Interactions and Optimal Working Relationships between Regional and Global NPP Groups
  • Examining the Full Set of Activities NPP Groups Perform, their Timing, intended Outcomes, and Value for the Organization
  • The Future of the NPP Function

Key Metrics
  • Organizational Demographics
  • Organizational Structure of NPP Function
  • Number of FTEs Working in NPP Groups
  • NPP's Portfolio Role: Responsible or Consulted?
  • Development Phases where Market Planning Activities are Conducted
  • Development Phases where Market Research Activities are Conducted
  • Development Phases where Medical Marketing Activities are Conducted
  • Development Phases where Brand Strategy Activities are Conducted
  • NPP's Role and Influence in Shaping Portfolio Decisions

Sample Key Findings

Structure

  • Involving NPP early in the development process speeds decision-making and allows low-value projects to be pruned.
  • NPP needs to be part of core team (with R&D, Clinical, etc) that shapes product development.

    Function
  • NPP groups should follow a fairly standard set of procedures to evaluate the commercial viability of drugs in development. Variations occur based on the particular characteristics of a drug or therapeutic program

    Market Planning Activities
    Begin development of Target Product Profile (TPP) as early as possible in Pre-Clinical in order to:
  • Assess how mechanism of action may be different or better than existing options
  • Establish a “threshold of success” that must be met in order to have a viable product (or to kill project)
  • Adjust as other products appear or as data changes
  • Focus in Phases 1 and 2 on the level of appropriate dosing and delivery method
  • Provide a foundation for effective positioning, publications, messaging, etc. later (Phase 3)

Methodology
Best Practices, LLC used both field surveys and interviews to complete this study. In all, 27 New Product Planning leaders at 25 different companies across the globe contributed data. In-depth interviews were conducted with leaders from 13 of the participating companies.


Sales and Marketing > New Product Development and Launch > Managing Development Process > Development Activities

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Consumer Products

Companies Profiled:
Abbott; Actelion; Alcon; Allergan; Almirall; Altus Biologics; Amgen; Astellas; Auxilium; Bayer Healthcare; Biogen Idec; Daiichi Sankyo; Eli Lilly; Human Genome Sciences; Merck; Novartis; Ortho Biotech; Sanofi-aventis; Stiefel; Takeda Pharmaceuticals; Theravance; UCB Pharma; Victory; Wyeth Pharmaceuticals

Special Offer: If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call Benjamin Gregory at 919-767-9160 if you have any questions.



Other Research in:
Sales and Marketing > New Product Development and Launch > Managing Development Process > Development Activities
Select items of interest and click the "Add Selected Items to Cart" button below.

Fixed Dose Combination Products: Successful Strategies for Developing and Bringing FDC Products to Market 
Non-members: Click here to review a complimentary excerpt from "Fixed Dose Combination Products: Successful Strategies for Developing and Bringing FDC Products to Market" STUDY OVERVIEW The economic advisability of developing fixed dose combination products can be difficult to determine owing to the many associated development and commercial challenges... (ID 5096)
Companies Profiled: Abbott, Xanodyne Pharmaceuticals, Victory, Valeant, more ...
Price: $4100.00   Free Excerpt Available


Pharmaceutical Early-Stage Commercialization: Structure & Functions That Lead to Success 
Non-members: Click here to review a complimentary excerpt of "Pharmaceutical Early-Stage Commercialization: Structure & Functions that Lead to Success" STUDY OVERVIEW Long and costly product development cycles make it essential for pharmaceutical companies to maximize limited staff and resources to the development of compounds with the greatest potential market value... (ID 5020)
Companies Profiled: Abbott Laboratories, Allergan, Alexion Pharmaceuticals, Altus Biologics, more ...
Price: $2598.00   Free Excerpt Available


Pharmaceutical New Product Planning: Structure and Activities to Drive Growth & Profitability 
Non-members: Click here for a complimentary excerpt of Pharmaceutical New Product Planning: Structure and Activities to Drive Growth & Profitability Study Overview Pharmaceutical and biotech companies are increasingly under pressure to deliver effective new products in shorter time frames while minimizing development costs... (ID 5008)
Companies Profiled: Abbott, Actelion, Alcon, Allergan, more ...
Price: $9000.00   Free Excerpt Available


Best Practices in New Product Commercialization 
Non-members: Click here for a complimentary excerpt of Best Practices in New Product Commercialization... (ID 5001)
Companies Profiled: Abbott, Allergan, Alexion Pharmaceuticals, Altus Biologics, more ...
Price: $4995.00   Free Excerpt Available


Critical Success Factors in Corporate Marketing 
Study Overview To ensure future growth and profitability, companies are trying to strengthen and revitalize their brand images, refocus sales forces and streamline marketing processes... (ID 4701)
Companies Profiled: Ford Motor Company, Pepsi, DuPont, SAS Institute, more ...
Price: $539.00


Commercializing New Products, Allocating Resources, and Managing the Product Life Cycle 
Study Overview Top companies find that developing yearly business plans for all products in the development pipeline allow companies to budget all resources, thereby reducing waste and idle resources... (ID 4682)
Companies Profiled: Eli Lilly, Pfizer, Amgen, Janssen
Price: $1278.95


Organizing for International Product Development and Deployment 
Based on a survey of 65 diverse organizations, this 17-slide presentation shows how global companies with multiple business units consistently organize and coordinate new product development activities... (ID 4535)
Companies Profiled: Abbott, Janssen Cilag Pharmaceutical, Bank of Guam, Sage, more ...
Price: $604.95


DNA Technology Lab Profiles 
This 21-page presentation profiles 20 of the top DNA technology labs... (ID 4512)
Companies Profiled: Canjii, Boehringer-Ingelheim, ATP, Affymetrix, more ...
Price: $299.95


Genetics Trends: Expert Insights and Lessons Learned 
This 21-slide presentation presents results of qualitative interviews with experts from the DNA technology field who make predictions for the next 10 years... (ID 4511)
Companies Profiled: ATP, Johns Hopkins, Cal Tech, Stanford University, more ...
Price: $574.95


Gene Maps: DNA Technology Survey Analysis 
This 39-slide presentation includes findings and forecasting on gene maps and DNA technology... (ID 4510)
Companies Profiled: Boehringer-Ingelheim, Vysis, Stratagene, Celera, more ...
Price: $891.95


Managing Market Planning for New Oncology Products 
The Business Excellence Board prepared this research on market planning for oncology products... (ID 4380)
Companies Profiled: AstraZeneca, Sanofi-aventis, Bayer, Bristol-Myers Squibb, more ...
Price: $524.00




All contents copyright © 1999-2013 Best Practices, LLC 6350 Quadrangle Drive, Chapel Hill, NC 27517 USA (919) 403-0251.
Site Map | Please see our Terms and Conditions of Use and Privacy Policy.

This site is optimized for 4.0 and higher versions of Microsoft Internet Explorer and Netscape Navigator.
If you experience difficulties using our e-commerce system, please check your browser version and our FAQs.